Form 4: PURE Bioscience Director Acquires Stock Options

Director Bernard Blotner acquired stock options in PURE Bioscience, Inc. on August 20, 2024.

Summary

• On August 20, 2024, Bernard Blotner, a director of PURE Bioscience, Inc., acquired stock options to purchase 125,000 shares of common stock.
• The exercise price of these options is $0.07 per share.
• The options vest in two tranches: 50% on the earlier of January 15, 2025, or the 2025 annual meeting date, and the remaining 50% on the earlier of January 15, 2026, or the 2026 annual meeting date.
• The options expire on August 20, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants. While insider ownership can be a positive signal, this specific event is more about compensation than a strong buy signal.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the compensation and ownership structure of the company's leadership.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in publicly traded companies, particularly in smaller companies like PURE Bioscience.
• The vesting schedule of the options (50% vesting annually over two years) is a fairly standard practice.
• The exercise price of $0.07 is likely related to the current market price of PURE stock at the time of the grant.

Stakeholder Impact

• The granting of stock options could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates

Keywords

stock options, director, PURE Bioscience, beneficial ownership, Form 4, acquisition